Evidence map›Paper›PMID 39166490›Full record

ArticleThe Journal of clinical endocrinology and metabolism2025

Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.

Merel T Stegenga, Lindsey Oudijk, Evert F S van Velsen, Robin P Peeters, Marco Medici, Frederik A Verburg, Tessa M van Ginhoven, Folkert J van Kemenade, W Edward Visser

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Merel T StegengaErasmus MC Academic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.ORCID 0009-0008-1096-8564
Lindsey OudijkErasmus MC Academic Center for Thyroid Diseases, Department of Pathology, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.ORCID 0000-0001-6168-2381
Evert F S van VelsenErasmus MC Academic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.ORCID 0000-0002-6938-065X
Robin P PeetersErasmus MC Academic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.ORCID 0000-0001-7732-9371
Marco MediciErasmus MC Academic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.ORCID 0000-0002-7271-7858
Frederik A VerburgErasmus MC Academic Center for Thyroid Diseases, Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.
Tessa M van GinhovenErasmus MC Academic Center for Thyroid Disease, Department of Surgery, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.
Folkert J van KemenadeErasmus MC Academic Center for Thyroid Diseases, Department of Pathology, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.ORCID 0000-0002-4225-4354
W Edward VisserErasmus MC Academic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 3015GDThe Netherlands.ORCID 0000-0002-5248-863X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe 2022 WHO Classification categorizes oncocytic (OTC) and follicular thyroid carcinoma (FTC), based on the degree of capsular and vascular invasion, into minimally invasive (MI), encapsulated angio-invasive (EA), and widely invasive tumors (WI). While associations with clinical outcomes have been studied extensively in FTC, robust clinical data are lacking for OTC. We aimed to investigate the impact of the reclassification of OTC and FTC by the 2022 WHO Classification on clinical outcomes.

methodsAll adult OTC and FTC patients treated at the Erasmus MC (the Netherlands) between 2000 and 2016 were retrospectively included. All tumors were extensively revised by 2 independent pathologists, facilitated by Palga: Dutch Pathology Databank. Kaplan-Meier curves were used to study the association of the 2004 and 2022 WHO Classification with overall survival, disease-specific survival (DSS), recurrence-free survival, and radioactive iodine (RAI)-refractory disease.

resultsAmong 52 OTC and 89 FTC patients, 15 (28.8%) OTC and 34 (38.2%) FTC tumors were reclassified as EAOTC or EAFTC. The 2022 WHO Classification substantially improved risk stratification in both subtypes for DSS, compared to the 2004 edition. Ten-year DSS rates were 100% for MIOTC, 92.9% for EAOTC, and 56.5% for WIOTC, compared to 100% (MIOTC) and 64.2% (WIOTC) following the 2004 WHO Classification. For FTC and RAI-refractory disease, similar trends were observed.

conclusionClassification of OTC and FTC into 3 subcategories as defined by the 2022 WHO Classification substantially improves discrimination between low-, intermediate-, and high-risk patients, especially for DSS and RAI-refractory disease.

Indexed as

Adenocarcinoma, FollicularAdenoma, OxyphilicThyroid NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansIodine RadioisotopesKaplan-Meier EstimateMaleMiddle AgedNetherlandsPrognosisRetrospective StudiesWorld Health OrganizationIodine Radioisotopesfollicular thyroid carcinomaoncocytic thyroid carcinomapathologysurvivalthyroid neoplasmsWHO Classification

Identifiers

PMID39166490
PMCPMC12012812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.